Retrospective study about 73consecutive patients treated by direct oral anticoagulant and admitted to an emergency room;Étude rétrospective concernant 73 patients traités par un anticoagulant oral direct admis consécutivement dans un service d'urgence

Journal des Maladies Vasculaires

Volumn 40, Issue 1, 2015, Pages 1-9

  Moustafa, F ^a   Milhaud, G ^a   Dublanchet, N ^a,c   Lebreton, A ^b,c   Dutheil, F ^a   Schmidt, J ^a,c  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Bleeding; Direct oral anticoagulant; Emergency; Hemorrhage

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; DABIGATRAN; RIVAROXABAN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

AGE; AGED; ARTICLE; BEYTH SCORE; BLEEDING; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; CREATININE CLEARANCE; DESCRIPTIVE RESEARCH; DRUG USE; EMERGENCY CARE; FEMALE; GENDER; HAS BLED SCORE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; CHEMICALLY INDUCED; DRUG INTERACTION; EMERGENCY HEALTH SERVICE; FRANCE; HEMORRHAGE; HISTORY; HOSPITALIZATION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG INTERACTIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; FRANCE; HEMORRHAGE; HISTORY, ANCIENT; HOSPITALIZATION; HUMANS; MALE; MORPHOLINES; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THIOPHENES;

EID: 84923699944     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmv.2014.12.001     Document Type: Article

References (27)

1. Eriksson B.I., Kakkar A.K., Turpie A.G.G., Gent M., Bandel T.-J., Homering M., et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009, 91:636-644.
2. Wolowacz S.E., Roskell N.S., Plumb J.M., Caprini J.A., Eriksson B.I. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009, 101:77-85.
3. Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010ESC guidelines for the management of atrial fibrillation. Eur Heart J 2012, 33:2719-2747.
4. Lip G.Y., Andreotti F., Fauchier L., Huber K., Hylek E., Knight E., et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011, 106:997-1011.
5. Skanes A.C., Healey J.S., Cairns J.A., Dorian P., Gillis A.M., McMurtry M.S., et al. Focused 2012update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention andrate/rhythm control. Can J Cardiol 2012, 28:125-136.
6. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
7. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
8. Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE Disease. Chest 2012, 141:e419S-e494S.
9. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
10. EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., Büller H.R., Decousus H., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
11. EINSTEIN-PE Investigators, Büller H.R., Prins M.H., Lensin A.W.A., Decousus H., Jacobson B.F., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
12. Wallentin L., Yusuf S., Ezekowitz M.D., Alings M., Flather M., Franzosi M.G., et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010, 376:975-983.
13. Samama M.M., Conard J., Lillo-Le Louët A. Hemorrhagic accidents of the new oral anticoagulants and coagulation assays. J Mal Vasc 2013, 38:259-270.
14. Pernod G., Albaladejo P., Godier A., Samama C.M., Susen S., Gruel Y., et al. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)-March 2013. Arch Cardiovasc Dis 2013, 106:382-393.
15. Pisters R., Lane D.A., Nieuwlaat R., de Vos C.B., Crijns H.J.G.M., Lip G.Y.H. A novel user-friendly score (HAS-BLED) to assess one year risk of major bleeding in atrial fibrillation patients: the Euro-Heart Survey. Chest 2010, 138:1093-1100.
16. Lip G.Y., Frison L., Halperin J.L., Lane D. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation. The HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly) score. J Am Coll Cardiol 2011, 57:173-180.
17. Beyth R.J., Quinn L.M., Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998, 105:91-99.
18. Pernod G., Godier A., Gozalo C., Blanchard P., Sié P. Prise en charge des surdosages en antivitamines K, des situations à risque hémorragique et des accidents hémorragiques chez les patients traités par antivitamines K en ville et en milieu hospitalier. Recommandations HAS 2008. J Mal Vasc 2008, 33:S70-S71.
19. Soliman E.Z., Prineas R.J., Go A.S., Xie D., Lash J.P., Rahman M., et al. Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 2010, 159:1102-1107.
20. Beasley B.N., Unger E.F., Temple R. Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med 2011, 364:1788-1790.
21. Fox K.A.A., Piccini J.P., Wojdyla D., Becker R.C., Halperin J.L., Nessel C.C., et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011, 32:2387-2394.
22. Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., et al. Risk of bleeding with 2doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011, 123:2363-2372.
23. Halperin J.L., Hankey G.J., Wojdyla D.M., Piccini J.P., Lokhnygina Y., Patel M.R., et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF trial. Circulation 2014, 130:138-146.
24. Larsen T.B., Rasmussen L.H., Skjøth F., Due K.M., Callréus T., Rosenzweig M., et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation. J Am Coll Cardiol 2013, 61:2264-2273.
25. Alotaibi G.S., Almodaimegh H., McMurtry M.S., Wu C. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res 2013, 132:185-189.
26. Dans A.L., Connolly S.J., Wallentin L., Yang S., Nakamya J., Brueckmann M., et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation 2013, 127:634-640.
27. Jia B., Lynn H.S., Rong F., Zhang W. Meta-analysis of efficacy and safety of the new anticoagulants versus warfarin in patients with atrial fibrillation. J Cardiovasc Pharmacol 2014, 64:368-374.